Roche

RHHBY on OTC (US ADR; primary listing SIX Swiss Exchange: ROG)

Co-develops the amylin analogue petrelintide for obesity with Zealand Pharma.

Share price

$54.09

Up 19% over 12 months

What analysts expect

Buy

Buy50%

Hold50%

Sell0%

Price target for the next 12 months

384 CHFUp 1% compared with the current price

Price now 380 CHFAverage target

21 analysts. Targets are for the Swiss-listed share, in Swiss francs. The source shows no high or low. Source: MarketScreener, 20 Oct 2026. Targets are opinions and are often wrong.

Business

Yearly revenue: 63B CHF
Yearly profit: 12B CHF
Company value: $344B
Forward P/E: 18.4×As of 2026-10-21
Forward P/S: Not availableAs of 2026-10-21

Revenue and profit for the last twelve months reported.

Forward P/E compares the share price with forecast earnings per share. Forward P/S compares company value with forecast revenue. Both are dated estimates, separate from the live price. Missing or non-positive estimates are shown as unavailable.

Peptides in this book

PetrelintideTrials only

Logo source: Roche

Prices are delayed and figures rounded. Not investment advice.